作者
Kevin O Saunders, Robert J Edwards, Kedamawit Tilahun, Kartik Manne, Xiaozhi Lu, Derek W Cain, Kevin Wiehe, Wilton B Williams, Katayoun Mansouri, Giovanna E Hernandez, Laura Sutherland, Richard Scearce, Robert Parks, Maggie Barr, Todd DeMarco, Chloe M Eater, Amanda Eaton, Georgeanna Morton, Benjamin Mildenberg, Yunfei Wang, R Wes Rountree, Mark A Tomai, Christopher B Fox, M Anthony Moody, S Munir Alam, Sampa Santra, Mark G Lewis, Thomas N Denny, George M Shaw, David C Montefiori, Priyamvada Acharya, Barton F Haynes
发表日期
2022/9/7
期刊
Science translational medicine
卷号
14
期号
661
页码范围
eabo5598
出版商
American Association for the Advancement of Science
简介
A successful HIV-1 vaccine will require induction of a polyclonal neutralizing antibody (nAb) response, yet vaccine-mediated induction of such a response in primates remains a challenge. We found that a stabilized HIV-1 CH505 envelope (Env) trimer formulated with a Toll-like receptor 7/8 agonist induced potent HIV-1 polyclonal nAbs that correlated with protection from homologous simian-human immunodeficiency virus (SHIV) infection. The serum dilution that neutralized 50% of virus replication (ID50 titer) required to protect 90% of macaques was 1:364 against the challenge virus grown in primary rhesus CD4+ T cells. Structural analyses of vaccine-induced nAbs demonstrated targeting of the Env CD4 binding site or the N156 glycan and the third variable loop base. Autologous nAb specificities similar to those elicited in macaques by vaccination were isolated from the human living with HIV from which the …
引用总数